Can Fascaplysins Be Considered Analogs of Indolo[2,3-a]pyrrolo[3,4-c]carbazoles? Comparison of Biosynthesis, Biological Activity and Therapeutic Potential
Marine Drugs · 2025
DOI: 10.3390/md24010018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Marine Drugs, 2025. Verfasst von Maxim E Zhidkov und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Materials, Institute of High Technologies and Advanced Materials, FEFU Campus, Far Eastern Federal University, Ajax Bay 1…. Hauptthemen laut MEDLINE: Carbazoles, Indoles, Biological Products. Die Arbeit nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Far Eastern Federal University development program "Priority 2030", Far Eastern Federal University development program “Priority 2030”.
Abstract (Originalsprache)
For the first time, a comparative analysis has been conducted to elucidate the biosynthesis of three families of natural products—staurosporines/rebeccamycins, cladoniamides, and fascaplysins. Based on the available data, a well-founded hypothesis was formed that these metabolites arise through a shared biosynthetic pathway. A comparative evaluation of biological activity profiles and molecular mechanisms of action of the major representatives of these alkaloid families and their derivatives shows that, despite an apparent similarity between the activity spectra of indolo[2,3-a]pyrrolo[3,4-c]carbazoles and fascaplysins, they operate through different mechanisms. The biological effects of fascaplysin are driven primarily by the induction of metabolic stress rather than by the inhibition of DNA topoisomerase I or of a broad-spectrum protein kinases. The successful optimization of natural indolo[2,3-a]pyrrolo[3,4-c]carbazoles—compounds with initially poorer pharmacokinetic properties than those of fascaplysin—to drug-like candidates underscores the substantial pharmaceutical potential of the fascaplysin scaffold. Several existing fascaplysin derivatives, after the improvement of their pharmacokinetic characteristics, may serve as promising leads for the development of a new class of antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Materials, Institute of High Technologies and Advanced Materials, FEFU Campus, Far Eastern Federal University, Ajax Bay 10, Russky Island, 690922 Vladivostok, Russia.
- Departments of Biotechnology and Marine Natural Compounds Chemistry, G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of The Russian Academy of Sciences, 690922 Vladivostok, Russia.
ORCID-Profile: Oleg A Tryapkin
Förderung
- Ministry of Science and Higher Education of the Russian Federation
- Far Eastern Federal University development program "Priority 2030"
- Far Eastern Federal University development program “Priority 2030”
Zitieren
APA
Zhidkov, M. E., Popov, A. M., Soldatkina, O. A., Tryapkin, O. A., & Kharchenko, L. N. (2025). Can Fascaplysins Be Considered Analogs of Indolo[2,3-a]pyrrolo[3,4-c]carbazoles? Comparison of Biosynthesis, Biological Activity and Therapeutic Potential. Marine Drugs. https://doi.org/10.3390/md24010018
Vancouver
Zhidkov ME, Popov AM, Soldatkina OA, Tryapkin OA, Kharchenko LN. Can Fascaplysins Be Considered Analogs of Indolo[2,3-a]pyrrolo[3,4-c]carbazoles? Comparison of Biosynthesis, Biological Activity and Therapeutic Potential. Marine Drugs. 2025. doi:10.3390/md24010018
BibTeX
@article{Zhidkov2025,
author = {Zhidkov, Maxim E and Popov, Aleksandr M and Soldatkina, Olga A and Tryapkin, Oleg A and Kharchenko, Lyubov N},
title = {Can Fascaplysins Be Considered Analogs of Indolo[2,3-a]pyrrolo[3,4-c]carbazoles? Comparison of Biosynthesis, Biological Activity and Therapeutic Potential},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md24010018}
}
EUVIMED